# H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis

> **NCT05872841** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 38 (estimated)

## Conditions studied

- Primary Hepatocellular Carcinoma
- Portal Vein Thrombosis

## Interventions

- **DRUG:** Recombinant human adenovirus type 5 + TACE

## Key facts

- **NCT ID:** NCT05872841
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05872841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05872841, "H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05872841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*